Truck fleet insurer’s move to diversify gains traction
Sales of professional liability products are still a small part of total revenue but could reach $50 million by the end of 2013.
Sales of professional liability products are still a small part of total revenue but could reach $50 million by the end of 2013.
Massachusetts-based Hologic Inc., the company that bought Suros Surgical Systems Inc., will phase out its facility in Zionsville, bringing an end to 200 local jobs.
WellPoint Inc., the health insurer that’s lost 19 percent of its market value over two months, is the least popular carrier among hospital executives who have to negotiate with them, an industry survey shows.
Alph Bingham spent more than 28 years at Eli Lilly and Co. and from there co-founded InnoCentive Inc., a Massachusetts-based organization that organizes crowdsourcing to help companies solve internal challenges. The Carmel resident spoke about the challenges now facing pharmaceutical companies, which are buckling under ever-rising costs to develop drugs with lower rates of success and worsening prospects for reimbursement. Bingham’s solution is for pharma to embrace crowdsourcing and other “open innovation” concepts in order to spread the risk of R&D among more partners.
Columbus Regional Hospital saw wait times double in its emergency room after it began using electronic records in late June, according to the Associated Press. Even now, wait times are longer than usual, even though they have lessened.
Nearly half of employers in the sectors expect the Patient Protection & Affordable Care Act to boost their health plan costs more than 3 percent in 2014.
A WellPoint Inc. director said there’s no move by the board to fire CEO Angela Braly for poor performance. Meanwhile, an expert predicted Braly will have at least until early 2013 to right the ship as the company awaits the close of the $4.9 billion Amerigroup acquisition.
WellPoint Inc.’s Angela Braly is facing tough questions about her performance after the Indianapolis-based health insurer reported disappointing earnings last month and cut its 2012 forecast. Investors say Braly is the problem and some are calling for her ouster.
Odds are long that Eli Lilly and Co.’s leading Alzheimer’s drug will show positive results when its Phase 3 trial results are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a home run for Lilly.
Eli Lilly and Co. will book about $790 million in pretax income in the third quarter thanks to an early payment from former drug development partner Amylin Pharmaceuticals.
Dr. Craig Brater, 66, has worked at the Indianapolis-based school for 26 years, including the past 12 as dean. The school is the second largest medical school in the nation and the only one in Indiana.
Pfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second trial failure. Eli Lilly is developing a similar treatment.
The feds may be gaining on GOP governors who've balked at carrying out a key part of the health care overhaul law. Opponents of the law say they won't set up new private health insurance exchanges. But increasingly it's looking like Washington will do it for them.
The city that brought the world Prozac and other neuroscience drugs is doubling down on brain research with a new $52 million research center near Methodist Hospital.
Even though the potential payoff for health care innovation is less certain these days, the business case for new ways to produce more food has never been stronger. That’s the analysis that lies behind BioCrossroads' new report an agricultural innovation.
Indiana Gov. Mitch Daniels asked the three gubernatorial candidates this week for their input as he decides whether to establish a state health insurance exchange.
Indianapolis-based Baldwin & Lyons Inc. on Thursday reported a profitable second quarter, a year after a series of major natural catastrophes caused a big loss for the transportation industry insurer.
The Indianapolis drugmaker said its scientists are investigating whether dogs' sharp sense of smell allow them to detect changes in human chemistry.
The investor drubbing sustained by Hill-Rom Holdings Inc. last week stemmed not so much from the new acquisition it announced as from the gloomy outlook in the North American hospital market.
Austerity and upheaval in Europe have not hurt Eli Lilly and Co.’s $4 billion-a-year drug business there, but the company is moving forward with plans to survive a coming swoon anyway.